



Gel-One® Cross-linked Hyaluronate


The Next Generation of Viscosupplementation

When purity matters choose Gel-One® Cross-linked Hyaluronate

The purity of a hyaluronic acid product is an important criterion that can have significant clinical implications. Purity is not just about what a product is made from but also how it is made. The avian-sourced hyaluronan used in *Gel-One* Hyaluronate has undergone repeated purification processes to minimize impurities, including proteins and bacterial endotoxins. This specialized manufacturing reduces protein to undetectable levels, potentially reducing the risk of avian reactions.

Gel-One Hyaluronate has:

- Purity designed in through a manufacturing process that nearly eliminates all avian protein and bacterial endotoxins
- No reported pseudosepsis in the clinical trial and post-market experience to date
- The convenience of single injection



Impurity levels measured were below the detection limits of the tests.


The purity of *Gel-One* Hyaluronate provides the convenience of a single injection with a safety profile comparable to non-avian products, including no reported incidence of pseudosepsis in clinical study and post-market experience.

1. Data on file at SKK. The protein level was measured by LC/MC method with lower detection limit of .5 µg/mL

2. Ohshima et al., *Jpn Pharmacol Ther* 2004; Vol32, No.10: 655-662, The protein level was measured by Lowry method.

The Next Generation of Viscosupplementation

The innovative manufacturing process used to make *Gel-One* Hyaluronate creates the first and only fully cross-linked HA. Seikagaku's proprietary photo-gelation technology creates very large molecules that may greatly increase the total residence time of hyaluronic acid in the joint and surrounding tissues. Joint residence time is a measure of the total time from injection that a product can be detected in any part of the knee.



- ***Gel-One* Hyaluronate has the longest joint residence time of any of HA injection according to publicly available data^{3,4}**
- **No reported pseudosepsis in pre-clinical trial or post-marketing experience to date**
- **The convenience of single injection**

* Increased joint residence time has not been shown to lead to increased efficacy or duration of pain relief

3. *Gel-One* Hyaluronate data on file at Seikagaku Corporation, Tokyo, Japan.

4. Larsen NE et al. Clearance kinetics of a hyaln-based Viscosupplementation after intra-articular and intravenous administration in animal models. *Journal of Biomaterials Reserch B:Applied Biomaterials* 2012; 100B: 457-462

Gel-One® is a registered trademark of Seikagaku Corporation.
Synvisc-One® is a registered trademarks of Genzyme Corporation

97-1111-011-00 3-18-15 ©2015 Zimmer, Inc.

Contact your Zimmer Sales Representative
Call 1-800-348-2759 or email gelone@zimmer.com

